MPG.eBooks - Description: CADTH CDEC final recommendation: Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.)

Read Now

The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin be listed for the treatment of type 2 diabetes

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health October 15, 2015, 2015
Series:	CADTH common drug review
Subjects:	Glucosides / Therapeutic Use Canada Sodium-glucose Transporter 2 Inhibitors / Therapeutic Use Cost-benefit Analysis Benzhydryl Compounds / Therapeutic Use Diabetes Mellitus, Type 2 / Drug Therapy Treatment Outcome
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534039
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin be listed for the treatment of type 2 diabetes
Physical Description:	1 PDF file (6 pages)